Drug Profile


Alternative Names: ARN-509; JNJ-56021927; JNJ-927

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California System
  • Developer Case Comprehensive Cancer Center; Dana-Farber Cancer Institute; Institut Paoli-Calmettes; Janssen Research & Development
  • Class Antiandrogens; Antihormones; Antineoplastics; Aza compounds; Benzamides; Pyridines; Small molecules; Spiro compounds; Sulfhydryl compounds; Thiohydantoins
  • Mechanism of Action Androgen receptor antagonists; Hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Prostate cancer

Most Recent Events

  • 20 Oct 2017 Duke University Medical Center plans a phase II trial for Prostate cancer (Combination therapy, Second line therapy or greater) in USA (NCT03311555)
  • 11 Oct 2017 Preregistration for Prostate cancer (Hormone refractory, Second-line therapy or greater) in USA (PO)
  • 06 Oct 2017 VA Office of Research and Development plans a phase II trial for Prostate cancer (Newly diagnosed) in USA (NCT03298087)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top